Stefan Hendriks – Global Head Cell & Gene, Novartis…
Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in…
Tagged with CELL &
Embryonic Gene Editing: How Far is Too Far to Find a Treatment…
Rare disease patient advocate Monica Weldon outlines some of the ethical conundrums around embryonic gene editing. With CRISPR technology again in the…
Can Sweden take the lead in Precision Medicine?
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for…
Cell & Gene Therapy: CRISPR-Cas9 Nobel Prize Pioneers in…
On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A. Doudna “for the development…
Nicolaus Kröger – President, European Society for Blood…
Professor Nicolaus Kröger, president of the European Society for Blood and Marrow Transplantation (EBMT) introduces the multi-stakeholder GoCART…
Thomas D. Szucs, European Center of Pharmaceutical Medicine at…
Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the…
Ana Hidalgo-Simon – Head of Advanced Therapies, European…
The EMA’s Head of Advanced Therapies Dr Ana Hidalgo-Simon outlines Europe’s evolving regulatory framework for regenerative medicines, how it…
Four Cell & Gene Companies to Know in China
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese…
Cell & Gene Therapy: Command? Consent? Collaborate!
Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the…
Edigene CEO on Gene Editing Biotech’s Ambitious Expansion Plans
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and…
Japan: The Latest Therapeutic Applications in Induced Pluripotent…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive…
Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…
